Literature DB >> 12789406

Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnerships.

Robert G Ridley1.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12789406      PMCID： PMC1326445          DOI： 10.1038/sj.embor.embor858

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  8 in total

Review 1.  Reaching maturity - 25 years of the TDR.

Authors:  C M Morel
Journal:  Parasitol Today       Date:  2000-12

Review 2.  Drugs for neglected diseases: a failure of the market and a public health failure?

Authors:  P Trouiller; E Torreele; P Olliaro; N White; S Foster; D Wirth; B Pécoul
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

Review 3.  Medical need, scientific opportunity and the drive for antimalarial drugs.

Authors:  Robert G Ridley
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

4.  The development of Lapdap, an affordable new treatment for malaria.

Authors:  Trudie Lang; Brian Greenwood
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

5.  Strategic emphases for tropical diseases research: a TDR perspective.

Authors:  Jan H F Remme; Erik Blas; Lester Chitsulo; Philippe M P Desjeux; Howard D Engers; Thomas P Kanyok; Jane F Kayondo; Deborah W Kioy; Vasanthapuram Kumaraswami; Janis K Lazdins; Paul P Nunn; Ayoade Oduola; Robert G Ridley; Yeya T Toure; Fabio Zicker; Carlos M Morel
Journal:  Trends Microbiol       Date:  2002-10       Impact factor: 17.079

6.  Access to essential drugs in poor countries: a lost battle?

Authors:  B Pécoul; P Chirac; P Trouiller; J Pinel
Journal:  JAMA       Date:  1999-01-27       Impact factor: 56.272

7.  Oral miltefosine for Indian visceral leishmaniasis.

Authors:  Shyam Sundar; T K Jha; C P Thakur; Juergen Engel; Herbert Sindermann; Christina Fischer; Klaus Junge; Anthony Bryceson; Jonathan Berman
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

8.  Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria.

Authors:  P Winstanley
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622
  8 in total
  4 in total

Review 1.  Future trends and challenges in pathogenomics. A Foresight study.

Authors:  Sven Pompe; Judith Simon; Peter M Wiedemann; Christof Tannert
Journal:  EMBO Rep       Date:  2005-07       Impact factor: 8.807

2.  Ethics in public health research: a research protocol to evaluate the effectiveness of public-private partnerships as a means to improve health and welfare systems worldwide.

Authors:  Donald A Barr
Journal:  Am J Public Health       Date:  2006-11-30       Impact factor: 9.308

3.  Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.

Authors:  Gina S El-Feky; Wael S Mohamed; Hanaa E Nasr; Naglaa M El-Lakkany; Sayed H Seif El-Din; Sanaa S Botros
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

4.  Research on infectious diseases requires better coordination.

Authors:  Robert G Ridley
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.